Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® In Combination with Checkpoint Inhibitors for Metastatic Non-Small Cell Lung Cancer

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...
Pharmabiz

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ

ImmunityBio’s Anktiva receives Saudi FDA approval for non-muscle invasive bladder cancer with carcinoma in-situ: Culver City, California Friday, January 16, 2026, 15:00 Hrs [IST ...
Fierce Biotech

J&J junks $1.2B eczema therapy while Genmab clears out cancer drug

Johnson & Johnson and Genmab both used the festive period to junk therapies that haven’t lived up to their promise in the ...
Onlymyhealth on MSN

Cervical Cancer Awareness Month: HPV Explained Beyond Vaccine

Human Papillomavirus HPV infection causes almost all cases of cervical cancer Our expert explains what HPV is its causes ...
PharmiWeb

Saudi FDA Grants Accelerated Approval to ImmunityBio’s ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ

Approval of ANKTIVA was granted for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ, with ...
Idaho State Journal

Prism Family Medicine: Human Papillomavirus, Cervical Cancer and Evolving Prevention Strategies

Prior to the 1970s, researchers widely believed cervical cancer was caused by the herpes simplex virus. That understanding ...
Investing.com Australia

ImmunityBio stock rises after Saudi FDA approves ANKTIVA for lung cancer

Investing.com -- ImmunityBio (NASDAQ:IBRX) stock rose 6% Wednesday morning after the company announced that Saudi Arabia’s ...

Press Release Biocartis NV: Biocartis to collaborate with Mayo Clinic on breast cancer gene signatures

ESTBiocartis to collaborate with Mayo Clinic on breast cancer gene signaturesItasca, IL, US, 12 January 2026 – ...

Forlong Biotechology Announced Activation of Phase Ib/II Study of FL115 (IL-15 Superagonist) in combination with anti-PD-1 Antibody for Patients with Advanced Solid Tumor and ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients with severe unmet needs, today announced that its Phase Ib/II study of ...
Pharmabiz

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis

Boehringer Ingelheim begins phase IIa trial of BI 765423, a novel monoclonal antibody targeting IL-11, in patients with idiopathic pulmonary fibrosis: Ingelheim, Germany Thursday, ...